is a commonly-used antibiotic to treat hepatic encephalopathy(HE), a complex neuropsychiatric
syndrome caused by hepatic dysfunction.
Rifaximin reduces the production of gut ammonia, the main toxin in HE
pathogenesis. We hypothesized that the effect of rifaximin on
neurometabolic profile is dose-related. Therefore, in this study, the effects of rifaximin administered at 6x
assessed, in vivo and longitudinally
on brain metabolites in bile-duct ligated(BDL) rats using 1H-MRS at 9.4T,
biochemical and behavioral tests. They were compared with non-treated and
human-dose treated rats. We showed that higher-dose rifaximin treatment
was associated with positive effects on brain Gln,Glu and osmoregulation.